Results from the phase 3 AEGEAN trial led to the approval of neoadjuvant and adjuvant durvalumab for patients with resectable NSCLC.
Approval Alert | Perioperative Durvalumab in Resectable NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
3
QOL Improvement in Breast Cancer Noted With YES System
4
What is Cevostamab’s Mechanism of Action in Multiple Myeloma?
5
